Alkermes (ALKS)

Alkermes’ commercial portfolio has included therapies used in areas such as alcohol dependence, opioid dependence, schizophrenia, and bipolar disorder. The company also advances research and development programmes focused on neuroscience, seeking to address conditions with significant unmet need. Its work combines internal discovery and development capabilities with manufacturing know-how and, where appropriate, partnerships or licensing arrangements.

The company operates as a fully integrated biotech, meaning it participates across multiple stages of the pharmaceutical value chain, from research and clinical development through regulatory engagement, manufacturing, and commercial sales. Alkermes uses proprietary technologies to formulate medicines and may source active pharmaceutical ingredients from third parties or receive them through licensees before incorporating them into finished products.

The United States is the company’s largest commercial market, although Alkermes also has operations and revenue exposure connected to Ireland and other international markets. Its headquarters structure and operating footprint reflect the global nature of pharmaceutical development, manufacturing, intellectual property, and regulatory oversight.

For investors, Alkermes represents exposure to specialty pharmaceuticals and neuroscience-focused biotechnology rather than broad primary-care medicine. Its performance is shaped by prescription trends for marketed products, patent protection, payer coverage, regulatory decisions, clinical trial results, and the company’s ability to turn research assets into durable commercial medicines.